STOCK TITAN

Nanobiotix S.A. American Depositary Shares - NBTX STOCK NEWS

Welcome to our dedicated page for Nanobiotix S.A. American Depositary Shares news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix S.A. American Depositary Shares stock.

Nanobiotix S.A. (Euronext: NANO / ISIN: FR0011341205) is a leading clinical-stage nanomedicine company specializing in the development of groundbreaking approaches for cancer treatment. The company's core technology, NanoXray, augments the effectiveness of radiotherapy, offering a more efficient treatment option for cancer patients. The innovative NanoXray products are designed to be compatible with existing radiotherapy treatments and aim to treat a broad spectrum of solid tumors, such as soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma.

The primary product candidate, NBTXR3, is currently undergoing evaluation for its efficacy in treating soft tissue sarcoma, head and neck cancers, prostate cancer, and liver cancers (both primary and metastases). Additionally, Nanobiotix has partnered with PharmaEngine in Taiwan to conduct trials for head and neck cancer and rectal cancer in the Asia Pacific region.

Nanobiotix has also embarked on a preclinical research program in immuno-oncology, further expanding its portfolio and potential for transformative cancer therapies. NBTXR3 works by magnifying the effects of radiotherapy within tumor cells, thereby enhancing cancer treatment without increasing the dose to surrounding healthy tissues.

Recently, Nanobiotix has been focused on validating the safety and efficacy of RT-activated NBTXR3 by moving to global registration for LA-HNSCC, accounting for the majority of its operational and financial resources. The company plans to provide an updated global development plan for NBTXR3 after further alignment with the Joint Steering Committee (JSC).

In terms of financial performance, Nanobiotix has laid out a cautious strategy, ensuring that it remains well-funded to support ongoing and future operations. Their forward-looking statements highlight the potential risks and uncertainties that could affect their business and financial performance.

For the latest updates, Nanobiotix has scheduled a conference call and webcast on May 22, 2024, at 8:00 am EDT / 2:00 pm CEST. It continues to engage the market, providing transparency to shareholders through various media and regular updates on their progress and milestones.

To keep up with the latest news, visit www.nanobiotix.com.

Rhea-AI Summary

Nanobiotix plans to report its financial results for the half-year ending June 30, 2022, on September 28, 2022, after U.S. market close. A conference call and live audio webcast will follow on September 29, 2022, at 8:00 AM ET / 2:00 PM CET. The call will feature CEO Laurent Levy and CFO Bart Van Rhijn, discussing results and business updates. Interested participants can access the live webcast on the company’s website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.08%
Tags
-
Rhea-AI Summary

Nanobiotix (NASDAQ: NBTX) announced the recommended phase 2 dose for NBTXR3, which is set at 33% of gross tumor volume in three cohorts for treating head and neck squamous cell carcinoma (HNSCC). The company expects to submit a Phase 3 trial protocol to the FDA by Q1 2023, with updated clinical data from Study 1100 anticipated in Q4 2022. The ongoing study aims to evaluate NBTXR3 in combination with anti-PD-1 therapies for patients with recurrent or metastatic HNSCC, including those resistant to previous immunotherapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Nanobiotix reached an agreement to restructure €30.7 million in debt obligations from its 2018 loan with the European Investment Bank (EIB). This restructuring aims to align debt with development timelines, extending the maturity dates to June 2029 for principal repayments and October 2024 for interest payments. This extension will enhance Nanobiotix's operational runway into early 2024, allowing focus on lead programs for its cancer treatment, NBTXR3. Execution of the amendment is expected in Q4 2022, contingent on final legal documentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
none
Rhea-AI Summary

On August 31, 2022, Nanobiotix reported a total of 34,875,872 shares outstanding, with voting rights totaling 36,274,272 theoretical rights and 36,250,130 exercisable rights. This announcement aligns with regulations from the French Financial Markets Authority, ensuring transparency in shareholder voting. Nanobiotix focuses on innovative therapeutic approaches for cancer treatment, utilizing its nanoparticle technology, specifically targeting head and neck cancers. Investors can find further details on their official website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.01%
Tags
none
-
Rhea-AI Summary

Nanobiotix and LianBio have announced the enrollment of the first patient in the pivotal Phase 3 NANORAY-312 trial for NBTXR3, targeting elderly patients with locally advanced head and neck cancer ineligible for platinum-based chemotherapy. This trial will assess the effectiveness of NBTXR3 combined with radiotherapy and cetuximab. With a global enrollment goal of 500 patients, LianBio aims to enroll approximately 100 in Asia. Previous trials show promising survival rates, positioning NBTXR3 as a potential key treatment in a rapidly growing radiotherapy market in Asia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.69%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
none
Rhea-AI Summary

Nanobiotix (NASDAQ: NBTX), a late-stage biotechnology company, announced the participation of co-founder Laurent Levy and CFO Bart Van Rhijn at the H.C. Wainwright 24th Annual Global Investment Conference in New York and virtually from September 12-14, 2022.

Their presentation is scheduled for September 12, 2022, at 2:00 PM ET. A live webcast will be available on the company's website, with a replay accessible within 48 hours.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.01%
Tags
conferences
-
Rhea-AI Summary

Nanobiotix has announced the total outstanding shares as of July 31, 2022, amounting to 34,875,872. The total number of voting rights is reported as 36,274,272 (theoretical) and 36,299,593 (exercisable). This financial disclosure aligns with the regulatory requirements under French commercial law. The company focuses on innovative treatments through its nanoparticle platform, particularly for solid tumors and head and neck cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
none
-
Rhea-AI Summary

NANOBIOTIX (NASDAQ: NBTX) released its Half-Year report on its liquidity contract with Gilbert Dupont. As of June 30, 2022, the liquidity account held 25,706 shares and a cash balance of €60,051.07. In the first half of 2022, the total buy side traded volume reached 306,341 shares, amounting to €1,883,900.28, while the sell side traded volume was 296,091 shares, totaling €1,846,535.38. Comparatively, as of December 31, 2021, the account held 15,456 shares and €97,415.97 in cash. The report complies with AMF Decision N°2021-01 on liquidity contracts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
none
Rhea-AI Summary

Nanobiotix, traded on NASDAQ as NBTX, reported its share structure as of June 30, 2022. The total number of outstanding shares is 34,875,872, with 36,329,077 theoretical voting rights and 36,303,371 exercisable voting rights. This data is critical for investors tracking corporate governance and voting processes. Nanobiotix is dedicated to innovative cancer therapies, particularly focusing on head and neck cancers using its proprietary nanoparticle platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of Nanobiotix S.A. American Depositary Shares (NBTX)?

The current stock price of Nanobiotix S.A. American Depositary Shares (NBTX) is $3.1 as of December 20, 2024.

What is the market cap of Nanobiotix S.A. American Depositary Shares (NBTX)?

The market cap of Nanobiotix S.A. American Depositary Shares (NBTX) is approximately 158.1M.

What is Nanobiotix S.A. known for?

Nanobiotix S.A. specializes in developing nanomedicine technologies for enhancing the efficacy of radiotherapy in treating cancer.

What is NanoXray technology?

NanoXray technology is a proprietary innovation by Nanobiotix that enhances the energy of radiotherapy to provide more efficient cancer treatment.

What types of cancer does NBTXR3 target?

NBTXR3 targets a variety of solid tumors, including soft tissue sarcoma, head and neck cancers, prostate cancer, and liver cancers.

Who is Nanobiotix partnered with in the Asia Pacific region?

Nanobiotix has partnered with PharmaEngine in Taiwan to conduct trials for head and neck cancer and rectal cancer.

What recent projects are Nanobiotix involved in?

Nanobiotix is focused on validating the safety and efficacy of RT-activated NBTXR3 and moving towards global registration for LA-HNSCC.

When is the next conference call and webcast scheduled?

The next conference call and webcast is scheduled for May 22, 2024, at 8:00 am EDT / 2:00 pm CEST.

How does NBTXR3 enhance radiotherapy?

NBTXR3 magnifies the effect of radiotherapy within tumor cells while minimizing the radiation dose to surrounding healthy tissues.

What is the significance of Nanobiotix’s preclinical research program?

Nanobiotix's preclinical research program in immuno-oncology aims to expand the potential for innovative cancer therapies by leveraging their nanotechnology.

Where can I find more information about Nanobiotix?

For more information, visit Nanobiotix's official website at www.nanobiotix.com.

Nanobiotix S.A. American Depositary Shares

Nasdaq:NBTX

NBTX Rankings

NBTX Stock Data

158.09M
46.87M
13.54%
0.06%
Biotechnology
Healthcare
Link
United States of America
Paris